# Real-world efficacy and safety of TYSABRI SC vs. IV
Keywords: TYSABRI, subcutaneous, intravenous, multiple sclerosis, RRMS, efficacy, safety, MS treatment

> This page presents a retrospective cohort study comparing the real-world efficacy and safety of TYSABRI (natalizumab) administered subcutaneously versus intravenously in patients with highly active relapsing-remitting multiple sclerosis (RRMS), alongside expert insights from Dr. Tarunya Arun.

## Details
- [Real-world efficacy and safety of TYSABRI SC vs. IV](#): A study presented at ECTRIMS 2024 found similar effectiveness and safety for subcutaneous and intravenous administration in managing RRMS.
- [ECTRIMS 2024 poster presentation](#): Dr. Arun discusses the study findings on the efficacy of subcutaneous versus intravenous TYSABRI administration.
- [TYSABRI and the MS management landscape](#): Insights into patient suitability for TYSABRI treatment and its efficacy and safety profiles.
- [Q&A with Dr Tarunya Arun](#): Dr. Arun shares her experience in switching RRMS patients from TYSABRI IV to SC and discusses future challenges in MS treatment.
- [Switching patients from TYSABRI IV to SC](#): Presentation of the first real-world cohort study on clinical outcomes for patients switching from intravenous to subcutaneous TYSABRI.
- [TYSABRI SC administration outside clinical settings](#): Following a license update in April 2024, TYSABRI SC may now be administered outside of clinical settings for eligible patients.
- [About the speaker](#): Dr. Tarunya Arun, a Consultant Neurologist, shares her expertise and research interests in neuroinflammatory diseases and MS treatments.